TriSalus Life Sciences, Inc.
TLSI
$5.73
$0.081.42%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 44.40% | 41.52% | 59.67% | 116.39% | 77.34% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 44.40% | 41.52% | 59.67% | 116.39% | 77.34% |
| Cost of Revenue | 108.93% | 70.46% | 18.13% | 46.68% | -28.68% |
| Gross Profit | 37.09% | 37.81% | 68.02% | 136.26% | 113.24% |
| SG&A Expenses | 15.14% | -2.81% | 18.74% | 66.36% | 47.13% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -12.07% | -26.36% | -3.17% | 38.44% | 33.32% |
| Operating Income | 34.70% | 51.03% | 28.51% | -15.45% | -21.26% |
| Income Before Tax | 71.63% | -68.56% | 69.02% | -59.75% | -58.14% |
| Income Tax Expenses | -200.00% | -- | -46.15% | 160.00% | -83.33% |
| Earnings from Continuing Operations | 71.64% | -68.35% | 69.00% | -59.88% | -58.10% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 71.64% | -68.35% | 69.00% | -59.88% | -58.10% |
| EBIT | 34.70% | 51.03% | 28.51% | -15.45% | -21.26% |
| EBITDA | 35.17% | 51.69% | 29.28% | -15.70% | -20.63% |
| EPS Basic | 74.80% | 15.47% | 99.40% | -5.33% | 97.91% |
| Normalized Basic EPS | 64.33% | 91.18% | 97.69% | 30.12% | 98.31% |
| EPS Diluted | 74.80% | 15.47% | 99.40% | -5.33% | 97.91% |
| Normalized Diluted EPS | 64.33% | 91.18% | 97.69% | 30.12% | 98.31% |
| Average Basic Shares Outstanding | 18.59% | 101.18% | 5,255.97% | 44.27% | 6,761.19% |
| Average Diluted Shares Outstanding | 18.59% | 101.18% | 5,255.97% | 44.27% | 6,761.19% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |